Clinical Site Overload: What’s Slowing Down Your Trial?

Vineet Bhatt03 Oct, 2025Technology

Site burden isn’t just a site problem—it’s a sponsor problem. For emerging biotech companies, every delay in enrollment or protocol deviation can jeopardize funding, partnerships, and patient access. You can’t afford to lose time or data quality to administrative overload at the site level. Instead of handing sites a fragmented tech stack and expecting seamless execution, sponsors must treat sites as strategic partners.